| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.713 | 0.006 | 0.713 | 5 Hydroxytryptamine release stimulant | 0.601 0.014 DBMET01575 | ||
| 0.583 | 0.009 | 0.583 | GABA C receptor rho-3 antagonist | 0.516 0.022 DBMET01575 | ||
| 0.561 | 0.024 | 0.565 | Aldehyde oxidase inhibitor | 0.565 0.024 DBMET01575 | DBMET01575 | |
| 0.489 | 0.005 | 0.489 | 5 Hydroxytryptamine agonist | 0.255 0.01 DBMET01575 | ||
| 0.488 | 0.014 | 0.521 | Superoxide dismutase inhibitor | 0.521 0.011 DBMET01575 | DBMET01575 | |
| 0.461 | 0.009 | 0.461 | Calcium channel activator | 0.431 0.015 DBMET01575 | ||
| 0.487 | 0.04 | 0.487 | Antiobesity | 0.324 0.101 DBMET01575 | ||
| 0.48 | 0.039 | 0.48 | 5 Hydroxytryptamine release inhibitor | 0.415 0.069 DBMET01575 | ||
| 0.477 | 0.045 | 0.477 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.387 0.112 DBMET01575 | ||
| 0.435 | 0.018 | 0.435 | Psychostimulant | 0.278 0.049 DBMET01575 | ||
| 0.419 | 0.011 | 0.419 | 5 Hydroxytryptamine uptake stimulant | 0.409 0.013 DBMET01575 | ||
| 0.384 | 0.005 | 0.384 | 5 Hydroxytryptamine 7 antagonist | 0.204 0.012 DBMET01575 | ||
| 0.361 | 0.014 | 0.361 | 5 Hydroxytryptamine antagonist | 0.185 0.038 DBMET01575 | ||
| 0.436 | 0.091 | 0.436 | Caspase 9 stimulant | 0.433 0.092 DBMET01575 | ||
| 0.346 | 0.011 | 0.346 | 5 Hydroxytryptamine 1E antagonist | 0.317 0.02 DBMET01575 | ||
| 0.342 | 0.008 | 0.342 | NADPH oxidase inhibitor | 0.317 0.01 DBMET01575 | ||
| 0.324 | 0.003 | 0.324 | 5 Hydroxytryptamine 3A agonist | 0.254 0.005 DBMET01575 | ||
| 0.322 | 0.003 | 0.322 | 5 Hydroxytryptamine 2C agonist | 0.213 0.004 DBMET01575 | ||
| 0.33 | 0.012 | 0.33 | Antiadrenergic | 0.229 0.019 DBMET01575 | ||
| 0.328 | 0.011 | 0.328 | Adrenaline antagonist | 0.226 0.019 DBMET01575 | ||
| 0.327 | 0.014 | 0.327 | 5 Hydroxytryptamine 2 antagonist | 0.205 0.029 DBMET01575 | ||
| 0.315 | 0.005 | 0.315 | 5 Hydroxytryptamine 1F antagonist | 0.125 0.022 DBMET01575 | ||
| 0.345 | 0.039 | 0.345 | HERG channel blocker | |||
| 0.311 | 0.008 | 0.311 | 5 Hydroxytryptamine 2C antagonist | 0.198 0.018 DBMET01575 | ||
| 0.3 | 0.005 | 0.3 | 5 Hydroxytryptamine 3E antagonist | 0.234 0.024 DBMET01575 | ||
| 0.329 | 0.036 | 0.329 | Interleukin agonist | 0.296 0.05 DBMET01575 | ||
| 0.298 | 0.015 | 0.298 | 5 Hydroxytryptamine 2B antagonist | 0.214 0.024 DBMET01575 | ||
| 0.329 | 0.046 | 0.329 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.28 0.079 DBMET01575 | ||
| 0.297 | 0.016 | 0.297 | Alpha adrenoreceptor antagonist | 0.191 0.029 DBMET01575 | ||
| 0.307 | 0.026 | 0.307 | MAP-kinase-activated kinase 5 inhibitor | 0.251 0.059 DBMET01575 | ||
| 0.29 | 0.01 | 0.29 | Alpha 2b adrenoreceptor antagonist | 0.208 0.022 DBMET01575 | ||
| 0.286 | 0.015 | 0.286 | 3C-like protease (Human coronavirus) inhibitor | 0.184 0.062 DBMET01575 | ||
| 0.278 | 0.007 | 0.278 | 5 Hydroxytryptamine uptake inhibitor | 0.103 0.025 DBMET01575 | ||
| 0.272 | 0.005 | 0.272 | Dopamine D4 agonist | 0.096 0.015 DBMET01575 | ||
| 0.277 | 0.013 | 0.277 | 5 Hydroxytryptamine 2A antagonist | 0.147 0.029 DBMET01575 | ||
| 0.334 | 0.081 | 0.334 | Vasodilator, peripheral | 0.331 0.082 DBMET01575 | ||
| 0.301 | 0.049 | 0.301 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.262 | 0.014 | 0.262 | Alpha 1 adrenoreceptor antagonist | 0.164 0.027 DBMET01575 | ||
| 0.248 | 0.006 | 0.248 | Alpha adrenoreceptor agonist | 0.172 0.012 DBMET01575 | ||
| 0.259 | 0.019 | 0.259 | Toll-Like receptor 9 antagonist | 0.174 0.048 DBMET01575 | ||
| 0.246 | 0.009 | 0.246 | Alpha 2a adrenoreceptor antagonist | 0.179 0.017 DBMET01575 | ||
| 0.279 | 0.045 | 0.328 | Tyrosine 3 hydroxylase inhibitor | 0.328 0.022 DBMET01575 | DBMET01575 | |
| 0.28 | 0.046 | 0.28 | Anticonvulsant | |||
| 0.238 | 0.005 | 0.238 | 5 Hydroxytryptamine 3 antagonist | 0.059 0.037 DBMET01575 | ||
| 0.235 | 0.004 | 0.235 | 5 Hydroxytryptamine 2 agonist | 0.158 0.005 DBMET01575 | ||
| 0.268 | 0.04 | 0.268 | Neuropeptide Y2 antagonist | 0.238 0.069 DBMET01575 | ||
| 0.228 | 0.004 | 0.228 | 5 Hydroxytryptamine 2A agonist | 0.167 0.005 DBMET01575 | ||
| 0.236 | 0.013 | 0.236 | Alpha 1a adrenoreceptor antagonist | 0.127 0.028 DBMET01575 | ||
| 0.233 | 0.01 | 0.233 | Dopamine D4 antagonist | 0.144 0.018 DBMET01575 | ||
| 0.267 | 0.045 | 0.267 | Sigma receptor agonist | 0.148 0.087 DBMET01575 | ||
| 0.224 | 0.003 | 0.224 | 5 Hydroxytryptamine 3 agonist | 0.127 0.007 DBMET01575 | ||
| 0.234 | 0.02 | 0.234 | Toll-Like receptor antagonist | 0.156 0.052 DBMET01575 | ||
| 0.224 | 0.014 | 0.224 | Alpha 2c adrenoreceptor antagonist | 0.169 0.025 DBMET01575 | ||
| 0.323 | 0.114 | 0.323 | MAP kinase kinase 6 inhibitor | |||
| 0.256 | 0.049 | 0.256 | ErbB-1 antagonist | 0.236 0.059 DBMET01575 | ||
| 0.223 | 0.019 | 0.223 | GABA C receptor rho-2 antagonist | 0.174 0.048 DBMET01575 | ||
| 0.23 | 0.026 | 0.23 | Activin receptor-like kinase 2 inhibitor | 0.181 0.046 DBMET01575 | ||
| 0.218 | 0.015 | 0.218 | Alpha 2 adrenoreceptor antagonist | 0.142 0.03 DBMET01575 | ||
| 0.205 | 0.002 | 0.205 | 5 Hydroxytryptamine 2B agonist | 0.109 0.004 DBMET01575 | ||
| 0.208 | 0.006 | 0.208 | Alpha 1 adrenoreceptor agonist | 0.116 0.013 DBMET01575 | ||
| 0.231 | 0.029 | 0.273 | Phospholipase C inhibitor | 0.273 0.021 DBMET01575 | DBMET01575 | |
| 0.227 | 0.027 | 0.227 | Ribosomal protein S6 kinase inhibitor | 0.179 0.047 DBMET01575 | ||
| 0.259 | 0.061 | 0.331 | DNA synthesis inhibitor | 0.331 0.034 DBMET01575 | DBMET01575 | |
| 0.207 | 0.01 | 0.257 | Protein kinase C zeta inhibitor | 0.257 0.007 DBMET01575 | DBMET01575 | |
| 0.209 | 0.013 | 0.209 | NMDA receptor antagonist | 0.178 0.018 DBMET01575 | ||
| 0.209 | 0.014 | 0.209 | Alpha 1b adrenoreceptor antagonist | 0.131 0.026 DBMET01575 | ||
| 0.273 | 0.081 | 0.301 | Hypoxia-inducible factor 1 alpha inhibitor | 0.301 0.065 DBMET01575 | DBMET01575 | |
| 0.209 | 0.018 | 0.24 | Dopamine antagonist | 0.24 0.015 DBMET01575 | DBMET01575 | |
| 0.207 | 0.016 | 0.207 | 5 Hydroxytryptamine 1 antagonist | 0.107 0.034 DBMET01575 | ||
| 0.204 | 0.014 | 0.204 | 5 Hydroxytryptamine 1A antagonist | 0.11 0.029 DBMET01575 | ||
| 0.251 | 0.063 | 0.251 | Cyclic AMP phosphodiesterase inhibitor | 0.197 0.096 DBMET01575 | ||
| 0.191 | 0.007 | 0.191 | Cyclin B3 inhibitor | 0.18 0.008 DBMET01575 | ||
| 0.238 | 0.056 | 0.238 | Anesthetic general | 0.183 0.085 DBMET01575 | ||
| 0.192 | 0.012 | 0.192 | ALK inhibitor | 0.14 0.022 DBMET01575 | ||
| 0.199 | 0.02 | 0.218 | GABA C receptor agonist | 0.218 0.017 DBMET01575 | DBMET01575 | |
| 0.186 | 0.011 | 0.351 | Dopamine D1 antagonist | 0.351 0.005 DBMET01575 | DBMET01575 | |
| 0.2 | 0.025 | 0.2 | Glutamate receptor antagonist | 0.126 0.068 DBMET01575 | ||
| 0.297 | 0.125 | 0.297 | Histamine release inhibitor | 0.272 0.14 DBMET01575 | ||
| 0.175 | 0.005 | 0.175 | Nicotinic alpha4beta2 receptor antagonist | 0.123 0.016 DBMET01575 | ||
| 0.233 | 0.062 | 0.233 | MAP kinase kinase 2 inhibitor | 0.191 0.088 DBMET01575 | ||
| 0.222 | 0.053 | 0.222 | Focal adhesion kinase 2 inhibitor | 0.16 0.115 DBMET01575 | ||
| 0.173 | 0.005 | 0.173 | 5 Hydroxytryptamine 6 antagonist | 0.085 0.021 DBMET01575 | ||
| 0.275 | 0.108 | 0.275 | Cholesterol antagonist | 0.243 0.13 DBMET01575 | ||
| 0.183 | 0.017 | 0.183 | GABA C receptor antagonist | 0.162 0.024 DBMET01575 | ||
| 0.183 | 0.017 | 0.183 | Pregnane X receptor agonist | 0.148 0.057 DBMET01575 | ||
| 0.17 | 0.005 | 0.17 | Bromodomain-containing protein 2 inhibitor | 0.103 0.037 DBMET01575 | ||
| 0.171 | 0.007 | 0.171 | Lanosterol 14 alpha demethylase inhibitor | 0.123 0.028 DBMET01575 | ||
| 0.222 | 0.058 | 0.23 | Nitric-oxide synthase stimulant | 0.23 0.049 DBMET01575 | DBMET01575 | |
| 0.207 | 0.044 | 0.207 | Cytidine deaminase inhibitor | 0.132 0.089 DBMET01575 | ||
| 0.173 | 0.012 | 0.173 | Alpha 1d adrenoreceptor antagonist | 0.102 0.023 DBMET01575 | ||
| 0.17 | 0.009 | 0.17 | Histamine N-methyltransferase inhibitor | 0.128 0.024 DBMET01575 | ||
| 0.164 | 0.005 | 0.164 | Glycine receptor antagonist | 0.126 0.015 DBMET01575 | ||
| 0.178 | 0.019 | 0.195 | Dopamine D2 antagonist | 0.195 0.017 DBMET01575 | DBMET01575 | |
| 0.196 | 0.037 | 0.196 | Hexokinase inhibitor | 0.169 0.059 DBMET01575 | ||
| 0.185 | 0.026 | 0.185 | Neuropeptide Y1 antagonist | 0.162 0.049 DBMET01575 | ||
| 0.171 | 0.013 | 0.171 | Electrolyte absorption antagonist | 0.119 0.037 DBMET01575 | ||
| 0.171 | 0.013 | 0.198 | Transcription factor STAT6 inhibitor | 0.198 0.007 DBMET01575 | DBMET01575 | |
| 0.166 | 0.008 | 0.166 | Adrenaline uptake inhibitor | 0.085 0.024 DBMET01575 | ||
| 0.169 | 0.011 | 0.169 | 5 Hydroxytryptamine 1B antagonist | 0.086 0.031 DBMET01575 | ||
| 0.17 | 0.013 | 0.17 | NMDA 2 receptor antagonist | 0.155 0.015 DBMET01575 | ||
| 0.197 | 0.04 | 0.197 | ATPase inhibitor | 0.148 0.105 DBMET01575 | ||
| 0.168 | 0.012 | 0.168 | Acetylcholine nicotinic agonist | 0.111 0.03 DBMET01575 | ||
| 0.17 | 0.014 | 0.17 | GABA C receptor rho-1 antagonist | 0.129 0.033 DBMET01575 | ||
| 0.156 | 0.003 | 0.156 | Phospholipase D inhibitor | 0.133 0.004 DBMET01575 | ||
| 0.157 | 0.005 | 0.157 | 5 Hydroxytryptamine 3A antagonist | 0.074 0.037 DBMET01575 | ||
| 0.268 | 0.117 | 0.268 | Vasodilator, coronary | 0.239 0.146 DBMET01575 | ||
| 0.191 | 0.04 | 0.191 | Neurotensin receptor agonist | 0.191 0.04 DBMET01575 | ||
| 0.154 | 0.004 | 0.154 | Purinergic P2X4 antagonist | 0.106 0.004 DBMET01575 | ||
| 0.195 | 0.045 | 0.195 | Acetylcholine M1 receptor antagonist | 0.163 0.063 DBMET01575 | ||
| 0.153 | 0.004 | 0.153 | 5 Hydroxytryptamine 7 agonist | 0.08 0.013 DBMET01575 | ||
| 0.197 | 0.051 | 0.216 | Succinate dehydrogenase inhibitor | 0.216 0.038 DBMET01575 | DBMET01575 | |
| 0.184 | 0.04 | 0.184 | Nav1.2 sodium channel blocker | 0.111 0.094 DBMET01575 | ||
| 0.164 | 0.02 | 0.164 | Protein kinase C mu inhibitor | 0.116 0.045 DBMET01575 | ||
| 0.169 | 0.031 | 0.169 | Ferrochelatase inhibitor | 0.112 0.06 DBMET01575 | ||
| 0.141 | 0.007 | 0.141 | Alpha 2 adrenoreceptor agonist | 0.097 0.015 DBMET01575 | ||
| 0.183 | 0.049 | 0.183 | Cyclin-dependent kinase 8 inhibitor | 0.179 0.052 DBMET01575 | ||
| 0.143 | 0.011 | 0.143 | 5 Hydroxytryptamine 1A agonist | 0.045 0.032 DBMET01575 | ||
| 0.147 | 0.015 | 0.147 | Dopamine D3 antagonist | 0.111 0.022 DBMET01575 | ||
| 0.221 | 0.092 | 0.221 | Aryl hydrocarbon receptor agonist | |||
| 0.153 | 0.026 | 0.153 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.099 0.055 DBMET01575 | ||
| 0.143 | 0.016 | 0.149 | Dopamine agonist | 0.149 0.015 DBMET01575 | DBMET01575 | |
| 0.152 | 0.025 | 0.152 | Acetylcholine agonist | |||
| 0.141 | 0.015 | 0.141 | 5 Hydroxytryptamine 1 agonist | 0.045 0.041 DBMET01575 | ||
| 0.13 | 0.004 | 0.13 | Histamine H4 receptor antagonist | 0.054 0.025 DBMET01575 | ||
| 0.152 | 0.027 | 0.159 | AMP-activated protein kinase stimulant | 0.159 0.023 DBMET01575 | DBMET01575 | |
| 0.149 | 0.025 | 0.155 | Beta glucuronidase inhibitor | 0.155 0.023 DBMET01575 | DBMET01575 | |
| 0.152 | 0.028 | 0.152 | Activin receptor-like kinase 4 inhibitor | 0.104 0.077 DBMET01575 | ||
| 0.226 | 0.103 | 0.226 | Ca2+/calmodulin-dependent kinase IV inhibitor | |||
| 0.21 | 0.086 | 0.212 | RNA-directed DNA polymerase inhibitor | 0.212 0.083 DBMET01575 | DBMET01575 | |
| 0.136 | 0.014 | 0.136 | 5 Hydroxytryptamine 1D antagonist | 0.07 0.038 DBMET01575 | ||
| 0.141 | 0.02 | 0.179 | NADH dehydrogenase inhibitor | 0.179 0.013 DBMET01575 | DBMET01575 | |
| 0.146 | 0.025 | 0.146 | Hedgehog signaling inhibitor | |||
| 0.279 | 0.159 | 0.279 | Analgesic | |||
| 0.124 | 0.004 | 0.124 | Corticotropin releasing factor 2 receptor antagonist | 0.073 0.024 DBMET01575 | ||
| 0.129 | 0.01 | 0.129 | 5 Hydroxytryptamine 5A antagonist | 0.077 0.025 DBMET01575 | ||
| 0.153 | 0.035 | 0.157 | Death-associated protein kinase 1 inhibitor | 0.157 0.03 DBMET01575 | DBMET01575 | |
| 0.13 | 0.013 | 0.13 | Dopamine uptake inhibitor | 0.061 0.037 DBMET01575 | ||
| 0.226 | 0.11 | 0.226 | Gastrin inhibitor | |||
| 0.175 | 0.059 | 0.175 | Catenin beta inhibitor | 0.171 0.065 DBMET01575 | ||
| 0.148 | 0.033 | 0.148 | Protein kinase C gamma inhibitor | 0.111 0.061 DBMET01575 | ||
| 0.124 | 0.008 | 0.157 | NMDA receptor subunit 3B antagonist | 0.157 0.005 DBMET01575 | DBMET01575 | |
| 0.139 | 0.024 | 0.139 | Acetylcholine release stimulant | 0.109 0.068 DBMET01575 | ||
| 0.126 | 0.011 | 0.126 | 5 Hydroxytryptamine 5 antagonist | 0.067 0.029 DBMET01575 | ||
| 0.14 | 0.025 | 0.14 | Phosphodiesterase 7B inhibitor | |||
| 0.134 | 0.02 | 0.134 | MAP-kinase-activated kinase inhibitor | 0.081 0.061 DBMET01575 | ||
| 0.147 | 0.036 | 0.147 | Interleukin 8 antagonist | 0.142 0.039 DBMET01575 | ||
| 0.136 | 0.025 | 0.136 | Acetylcholine nicotinic antagonist | 0.083 0.051 DBMET01575 | ||
| 0.155 | 0.044 | 0.155 | Cyclooxygenase 3 inhibitor | 0.129 0.068 DBMET01575 | ||
| 0.115 | 0.004 | 0.115 | MDM2 inhibitor | 0.087 0.014 DBMET01575 | ||
| 0.179 | 0.068 | 0.179 | Tumour necrosis factor antagonist | 0.139 0.114 DBMET01575 | ||
| 0.174 | 0.067 | 0.514 | Peroxidase inhibitor | 0.514 0.008 DBMET01575 | DBMET01575 | |
| 0.123 | 0.017 | 0.123 | Neuronal nicotinic receptor antagonist | 0.083 0.034 DBMET01575 | ||
| 0.162 | 0.057 | 0.163 | CF transmembrane conductance regulator agonist | 0.163 0.056 DBMET01575 | DBMET01575 | |
| 0.149 | 0.045 | 0.149 | Ca2+-transporting ATPase inhibitor | 0.144 0.058 DBMET01575 | ||
| 0.144 | 0.039 | 0.144 | GABA receptor agonist | |||
| 0.108 | 0.004 | 0.108 | Potassium channel small-conductance Ca-activated activator | |||
| 0.171 | 0.069 | 0.31 | Heat shock protein 90 alpha antagonist | 0.31 0.013 DBMET01575 | DBMET01575 | |
| 0.109 | 0.007 | 0.109 | Toll-Like receptor 8 antagonist | 0.051 0.04 DBMET01575 | ||
| 0.111 | 0.01 | 0.114 | GABA B receptor agonist | 0.114 0.009 DBMET01575 | DBMET01575 | |
| 0.12 | 0.02 | 0.12 | MAP-kinase-activated kinase 2 inhibitor | 0.069 0.059 DBMET01575 | ||
| 0.189 | 0.088 | 0.189 | Neurotrophic factor enhancer | 0.187 0.09 DBMET01575 | ||
| 0.117 | 0.017 | 0.117 | Benzodiazepine agonist | |||
| 0.11 | 0.01 | 0.11 | Nicotinic neuronal receptor agonist | 0.051 0.044 DBMET01575 | ||
| 0.112 | 0.012 | 0.112 | NMDA 2C receptor antagonist | 0.098 0.016 DBMET01575 | ||
| 0.154 | 0.056 | 0.165 | Adenylate cyclase stimulant | 0.165 0.041 DBMET01575 | DBMET01575 | |
| 0.109 | 0.014 | 0.109 | Bcl2 antagonist | 0.078 0.034 DBMET01575 | ||
| 0.147 | 0.052 | 0.147 | Heat shock protein 70 antagonist | 0.14 0.074 DBMET01575 | ||
| 0.103 | 0.009 | 0.103 | Histamine agonist | |||
| 0.109 | 0.015 | 0.109 | Acetylcholine M5 receptor agonist | |||
| 0.128 | 0.035 | 0.133 | HIV-1 integrase (Overall Integration) inhibitor | 0.133 0.032 DBMET01575 | DBMET01575 | |
| 0.101 | 0.008 | 0.101 | Cyclin D1 inhibitor | 0.089 0.012 DBMET01575 | ||
| 0.122 | 0.03 | 0.122 | Pim-3 kinase inhibitor | 0.095 0.051 DBMET01575 | ||
| 0.181 | 0.088 | 0.181 | I kappa B kinase epsilon inhibitor | 0.179 0.09 DBMET01575 | ||
| 0.148 | 0.056 | 0.148 | Alpha-N-acetylglucosaminidase inhibitor | 0.148 0.056 DBMET01575 | ||
| 0.097 | 0.005 | 0.097 | 5 Hydroxytryptamine 3B antagonist | 0.036 0.025 DBMET01575 | ||
| 0.112 | 0.021 | 0.112 | Acetylcholine M4 receptor antagonist | |||
| 0.101 | 0.01 | 0.129 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.129 0.005 DBMET01575 | DBMET01575 | |
| 0.092 | 0.003 | 0.092 | Nicotinic alpha4 receptor agonist | 0.031 0.004 DBMET01575 | ||
| 0.136 | 0.047 | 0.25 | Cystathionine beta-synthase inhibitor | 0.25 0.015 DBMET01575 | DBMET01575 | |
| 0.103 | 0.015 | 0.103 | NMDA receptor glycine site agonist | 0.062 0.044 DBMET01575 | ||
| 0.102 | 0.015 | 0.102 | Vanilloid 4 agonist | |||
| 0.105 | 0.018 | 0.105 | Toll-Like receptor 7 antagonist | |||
| 0.09 | 0.003 | 0.09 | Alpha 1L adrenoreceptor agonist | 0.065 0.007 DBMET01575 | ||
| 0.141 | 0.055 | 0.141 | Antibacterial (Helicobacter pylori) | |||
| 0.113 | 0.027 | 0.113 | Glutamate release inhibitor | 0.11 0.03 DBMET01575 | ||
| 0.179 | 0.094 | 0.2 | DNA methylase inhibitor | 0.2 0.079 DBMET01575 | DBMET01575 | |
| 0.124 | 0.039 | 0.126 | Potassium channel (Ca-activated) activator | 0.126 0.038 DBMET01575 | DBMET01575 | |
| 0.1 | 0.016 | 0.1 | Calcium channel T-type blocker | |||
| 0.107 | 0.024 | 0.107 | Cyclin-dependent kinase 4 inhibitor | 0.089 0.03 DBMET01575 | ||
| 0.09 | 0.008 | 0.09 | Dopamine D3 agonist | 0.084 0.009 DBMET01575 | ||
| 0.138 | 0.056 | 0.138 | Nav1.3 sodium channel blocker | |||
| 0.216 | 0.134 | 0.235 | Insulysin inhibitor | 0.235 0.111 DBMET01575 | DBMET01575 | |
| 0.239 | 0.157 | 0.239 | Calpain 2 inhibitor | |||
| 0.115 | 0.034 | 0.115 | Histamine H1 receptor antagonist | |||
| 0.09 | 0.009 | 0.09 | 5 Hydroxytryptamine 4 antagonist | 0.069 0.018 DBMET01575 | ||
| 0.09 | 0.01 | 0.09 | Nicotinic receptor alpha4 subunit antagonist | 0.059 0.023 DBMET01575 | ||
| 0.087 | 0.007 | 0.087 | CC chemokine receptor 2B antagonist | 0.061 0.018 DBMET01575 | ||
| 0.126 | 0.047 | 0.126 | Sphingosine 1-phosphate receptor 2 agonist | |||
| 0.161 | 0.083 | 0.161 | Death-associated protein kinase 2 inhibitor | 0.142 0.125 DBMET01575 | ||
| 0.091 | 0.014 | 0.196 | Heat shock protein 90 beta antagonist | 0.196 0.004 DBMET01575 | DBMET01575 | |
| 0.091 | 0.014 | 0.091 | Exportin-1 inhibitor | |||
| 0.139 | 0.063 | 0.139 | Sodium channel (voltage-gated) blocker | |||
| 0.139 | 0.066 | 0.139 | Aurora-C kinase inhibitor | |||
| 0.085 | 0.011 | 0.085 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.092 | 0.018 | 0.092 | Protein kinase C beta inhibitor | 0.076 0.036 DBMET01575 | ||
| 0.092 | 0.019 | 0.092 | Cannabinoid CB1 receptor antagonist | |||
| 0.112 | 0.039 | 0.112 | Calcium antagonist | |||
| 0.088 | 0.016 | 0.088 | Cyclin-dependent kinase 6 inhibitor | 0.071 0.03 DBMET01575 | ||
| 0.116 | 0.044 | 0.157 | Creatine kinase inhibitor | 0.157 0.021 DBMET01575 | DBMET01575 | |
| 0.146 | 0.074 | 0.146 | MAP kinase 3 inhibitor | |||
| 0.082 | 0.011 | 0.092 | NMDA receptor subunit 3A antagonist | 0.092 0.009 DBMET01575 | DBMET01575 | |
| 0.105 | 0.034 | 0.157 | Adrenaline agonist | 0.157 0.013 DBMET01575 | DBMET01575 | |
| 0.075 | 0.004 | 0.075 | Nerve growth factor antagonist | 0.052 0.016 DBMET01575 | ||
| 0.076 | 0.005 | 0.076 | Vascular adhesion protein 1 inhibitor | |||
| 0.135 | 0.065 | 0.137 | Sphingosine 1-phosphate receptor 2 antagonist | 0.137 0.061 DBMET01575 | DBMET01575 | |
| 0.099 | 0.029 | 0.099 | Caspase 7 inhibitor | |||
| 0.142 | 0.072 | 0.145 | Mannose-6-phosphate isomerase inhibitor | 0.145 0.069 DBMET01575 | DBMET01575 | |
| 0.097 | 0.028 | 0.097 | T cell inhibitor | 0.088 0.042 DBMET01575 | ||
| 0.091 | 0.023 | 0.106 | MAP kinase kinase 7 inhibitor | 0.106 0.009 DBMET01575 | DBMET01575 | |
| 0.083 | 0.016 | 0.083 | Nicotinic receptor alpha7 subunit antagonist | 0.053 0.038 DBMET01575 | ||
| 0.15 | 0.084 | 0.15 | Polo-like kinase-3 inhibitor | |||
| 0.07 | 0.004 | 0.07 | Methionyl aminopeptidase 1 inhibitor | 0.037 0.015 DBMET01575 | ||
| 0.115 | 0.05 | 0.126 | Urease inhibitor | 0.126 0.039 DBMET01575 | DBMET01575 | |
| 0.084 | 0.018 | 0.084 | NMDA 2A receptor antagonist | 0.054 0.034 DBMET01575 | ||
| 0.119 | 0.055 | 0.119 | Nav1.5 sodium channel blocker | |||
| 0.189 | 0.125 | 0.189 | DNA damaging | 0.166 0.15 DBMET01575 | ||
| 0.106 | 0.043 | 0.106 | Insulin growth factor antagonist | 0.079 0.068 DBMET01575 | ||
| 0.085 | 0.022 | 0.085 | Acetylcholine M5 receptor antagonist | 0.067 0.034 DBMET01575 | ||
| 0.071 | 0.009 | 0.071 | CC chemokine 4 receptor antagonist | |||
| 0.077 | 0.016 | 0.077 | Cyclin A1 inhibitor | 0.064 0.031 DBMET01575 | ||
| 0.111 | 0.05 | 0.111 | Insulin receptor antagonist | |||
| 0.153 | 0.091 | 0.153 | Antipruritic | |||
| 0.069 | 0.009 | 0.069 | GABA B receptor antagonist | 0.041 0.032 DBMET01575 | ||
| 0.124 | 0.064 | 0.124 | DNA repair enzyme inhibitor | 0.117 0.079 DBMET01575 | ||
| 0.089 | 0.028 | 0.089 | Protein kinase C alpha inhibitor | |||
| 0.113 | 0.053 | 0.113 | Chemokine receptor antagonist | |||
| 0.108 | 0.049 | 0.108 | Antihistaminic | |||
| 0.127 | 0.068 | 0.13 | Cholinergic antagonist | 0.13 0.065 DBMET01575 | DBMET01575 | |
| 0.085 | 0.026 | 0.085 | NMDA receptor agonist | |||
| 0.117 | 0.059 | 0.117 | Polo-like kinase-4 inhibitor | |||
| 0.124 | 0.067 | 0.128 | Acetylcholine antagonist | 0.128 0.063 DBMET01575 | DBMET01575 | |
| 0.073 | 0.016 | 0.073 | 5 Hydroxytryptamine 1B agonist | 0.054 0.035 DBMET01575 | ||
| 0.099 | 0.042 | 0.099 | Insulin like growth factor 1 antagonist | |||
| 0.171 | 0.115 | 0.171 | Potassium channel blocker | |||
| 0.138 | 0.083 | 0.138 | Sphingosine 1-phosphate receptor 5 antagonist | 0.134 0.091 DBMET01575 | ||
| 0.107 | 0.051 | 0.107 | Pim-1 kinase inhibitor | |||
| 0.065 | 0.01 | 0.065 | Kainate receptor 2 antagonist | 0.031 0.029 DBMET01575 | ||
| 0.074 | 0.019 | 0.074 | Glucosylceramidase inhibitor | 0.057 0.035 DBMET01575 | ||
| 0.093 | 0.04 | 0.093 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.093 0.04 DBMET01575 | ||
| 0.087 | 0.034 | 0.09 | Check point kinase 1 inhibitor | 0.09 0.033 DBMET01575 | DBMET01575 | |
| 0.076 | 0.023 | 0.076 | GABA receptor antagonist | |||
| 0.063 | 0.01 | 0.063 | Alpha 1d adrenoreceptor agonist | 0.039 0.027 DBMET01575 | ||
| 0.076 | 0.023 | 0.076 | GABA A receptor antagonist | |||
| 0.078 | 0.025 | 0.078 | CDK4/cyclin D1 inhibitor | 0.076 0.027 DBMET01575 | ||
| 0.103 | 0.05 | 0.103 | Protein kinase C delta inhibitor | |||
| 0.088 | 0.035 | 0.088 | Cannabinoid receptor antagonist | |||
| 0.061 | 0.008 | 0.061 | Histamine H1 receptor agonist | |||
| 0.077 | 0.025 | 0.077 | Cyclin B1 inhibitor | 0.072 0.029 DBMET01575 | ||
| 0.15 | 0.098 | 0.15 | LIM domain kinase 1 inhibitor | |||
| 0.139 | 0.087 | 0.291 | Heat shock protein 90 antagonist | 0.291 0.011 DBMET01575 | DBMET01575 | |
| 0.1 | 0.049 | 0.1 | Alpha 2d adrenoreceptor antagonist | |||
| 0.171 | 0.12 | 0.176 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.176 0.116 DBMET01575 | DBMET01575 | |
| 0.065 | 0.014 | 0.065 | Potassium channel (Inward rectifier) activator | |||
| 0.099 | 0.048 | 0.099 | Histamine antagonist | |||
| 0.065 | 0.015 | 0.065 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.065 | 0.015 | 0.065 | Alpha 1b adrenoreceptor agonist | 0.051 0.033 DBMET01575 | ||
| 0.092 | 0.041 | 0.096 | D-Ala-D-Ala ligase inhibitor | 0.096 0.035 DBMET01575 | DBMET01575 | |
| 0.055 | 0.004 | 0.055 | Nicotinic alpha3beta4 receptor agonist | 0.041 0.009 DBMET01575 | ||
| 0.054 | 0.004 | 0.054 | Imidazoline I1 receptor antagonist | 0.022 0.012 DBMET01575 | ||
| 0.054 | 0.005 | 0.065 | Estrogen-related receptor beta antagonist | 0.065 0.004 DBMET01575 | DBMET01575 | |
| 0.238 | 0.189 | 0.323 | Antibacterial | 0.323 0.119 DBMET01575 | DBMET01575 | |
| 0.083 | 0.034 | 0.083 | CXC chemokine receptor antagonist | |||
| 0.062 | 0.014 | 0.062 | Potassium channel (ATP-sensitive) activator | |||
| 0.083 | 0.035 | 0.083 | MAP kinase 7 inhibitor | |||
| 0.053 | 0.004 | 0.053 | Nicotinic alpha4beta2 receptor agonist | 0.04 0.008 DBMET01575 | ||
| 0.06 | 0.011 | 0.06 | Parathyroid hormone antagonist | 0.049 0.023 DBMET01575 | ||
| 0.097 | 0.049 | 0.097 | Polo-like kinase-1 inhibitor | 0.09 0.062 DBMET01575 | ||
| 0.057 | 0.01 | 0.057 | p53 inhibitor | |||
| 0.052 | 0.004 | 0.052 | Histamine H4 receptor agonist | |||
| 0.063 | 0.016 | 0.063 | Cyclin D3 inhibitor | 0.052 0.02 DBMET01575 | ||
| 0.07 | 0.024 | 0.07 | Melanin-concentrating hormone receptor 1 antagonist | |||
| 0.056 | 0.01 | 0.056 | Phenylethanolamine N methyltransferase inhibitor | 0.043 0.024 DBMET01575 | ||
| 0.063 | 0.017 | 0.063 | Bromodomain-containing protein 3 inhibitor | |||
| 0.135 | 0.09 | 0.135 | Diuretic | |||
| 0.181 | 0.136 | 0.181 | Spasmolytic | |||
| 0.057 | 0.013 | 0.057 | Somatostatin 4 agonist | 0.036 0.027 DBMET01575 | ||
| 0.071 | 0.027 | 0.071 | Calcium channel P-type blocker | |||
| 0.066 | 0.022 | 0.066 | Dopamine transporter inhibitor | |||
| 0.057 | 0.013 | 0.09 | Dopamine D5 agonist | 0.09 0.005 DBMET01575 | DBMET01575 | |
| 0.087 | 0.044 | 0.087 | CC chemokine 5 receptor agonist | 0.083 0.055 DBMET01575 | ||
| 0.228 | 0.184 | 0.258 | 15-Lipoxygenase inhibitor | 0.258 0.158 DBMET01575 | DBMET01575 | |
| 0.12 | 0.077 | 0.147 | Toll-Like receptor 2 antagonist | 0.147 0.055 DBMET01575 | DBMET01575 | |
| 0.103 | 0.06 | 0.103 | Cyclin-dependent kinase 9 inhibitor | |||
| 0.048 | 0.005 | 0.048 | 5 Hydroxytryptamine 6 agonist | |||
| 0.07 | 0.027 | 0.07 | Acetylcholine muscarinic agonist | |||
| 0.061 | 0.019 | 0.061 | Nicotinic receptor alpha3 subunit antagonist | |||
| 0.064 | 0.023 | 0.064 | Lysine-specific demethylase 1A inhibitor | |||
| 0.09 | 0.049 | 0.09 | Myeloperoxidase inhibitor | 0.086 0.056 DBMET01575 | ||
| 0.08 | 0.039 | 0.08 | Glycine receptor agonist | 0.071 0.053 DBMET01575 | ||
| 0.047 | 0.007 | 0.047 | Tryptophan 5 hydroxylase inhibitor | 0.036 0.024 DBMET01575 | ||
| 0.165 | 0.125 | 0.165 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.114 | 0.074 | 0.125 | Acetylcholine muscarinic antagonist | 0.125 0.062 DBMET01575 | DBMET01575 | |
| 0.044 | 0.004 | 0.052 | Estrogen-related receptor gamma antagonist | 0.052 0.003 DBMET01575 | DBMET01575 | |
| 0.068 | 0.03 | 0.068 | Cyclin H inhibitor | |||
| 0.1 | 0.061 | 0.149 | UDP-glucose 4-epimerase inhibitor | 0.149 0.029 DBMET01575 | DBMET01575 | |
| 0.065 | 0.026 | 0.065 | Cyclin B inhibitor | 0.061 0.031 DBMET01575 | ||
| 0.06 | 0.021 | 0.076 | Dopamine D2 agonist | 0.076 0.015 DBMET01575 | DBMET01575 | |
| 0.048 | 0.01 | 0.058 | CF transmembrane conductance regulator antagonist | 0.058 0.005 DBMET01575 | DBMET01575 | |
| 0.05 | 0.013 | 0.05 | Heme oxygenase inhibitor | |||
| 0.065 | 0.027 | 0.065 | Pim-2 kinase inhibitor | |||
| 0.065 | 0.027 | 0.065 | Cyclin B2 inhibitor | 0.063 0.029 DBMET01575 | ||
| 0.071 | 0.034 | 0.071 | Phosphodiesterase VII inhibitor | |||
| 0.065 | 0.028 | 0.065 | CC chemokine 2 receptor antagonist | |||
| 0.044 | 0.007 | 0.044 | LFA antagonist | |||
| 0.121 | 0.084 | 0.121 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.055 | 0.019 | 0.055 | Kainate receptor antagonist | |||
| 0.075 | 0.038 | 0.075 | Nav1.7 sodium channel blocker | |||
| 0.064 | 0.027 | 0.064 | Sphingosine kinase 2 inhibitor | 0.053 0.041 DBMET01575 | ||
| 0.085 | 0.049 | 0.085 | Transforming growth factor beta 3 antagonist | |||
| 0.04 | 0.004 | 0.04 | Acid ceramidase inhibitor | 0.025 0.019 DBMET01575 | ||
| 0.058 | 0.023 | 0.058 | Topoisomerase II beta inhibitor | 0.058 0.023 DBMET01575 | ||
| 0.05 | 0.016 | 0.05 | Acid-sensing ion channel blocker | |||
| 0.055 | 0.021 | 0.055 | Glutamate (mGluR5) agonist | |||
| 0.057 | 0.023 | 0.057 | Acetylcholine M1 receptor agonist | |||
| 0.058 | 0.025 | 0.058 | Purinergic P2X antagonist | |||
| 0.066 | 0.033 | 0.066 | Glutamate (mGluR1) antagonist | |||
| 0.037 | 0.004 | 0.037 | Alpha 2a adrenoreceptor agonist | 0.023 0.008 DBMET01575 | ||
| 0.143 | 0.111 | 0.17 | DNA methyltransferase I inhibitor | 0.17 0.086 DBMET01575 | DBMET01575 | |
| 0.053 | 0.021 | 0.053 | Benzodiazepine antagonist | |||
| 0.064 | 0.033 | 0.064 | CDK4/cyclin D inhibitor | 0.064 0.033 DBMET01575 | ||
| 0.192 | 0.161 | 0.247 | 12-Lipoxygenase inhibitor | 0.247 0.111 DBMET01575 | DBMET01575 | |
| 0.047 | 0.016 | 0.047 | Protein kinase (CK1) epsilon inhibitor | |||
| 0.069 | 0.039 | 0.069 | Aryl hydrocarbon receptor antagonist | |||
| 0.115 | 0.084 | 0.154 | Amylase inhibitor | 0.154 0.062 DBMET01575 | DBMET01575 | |
| 0.063 | 0.033 | 0.063 | Ca(v)3.2 blocker | |||
| 0.053 | 0.023 | 0.112 | Dopamine D5 antagonist | 0.112 0.008 DBMET01575 | DBMET01575 | |
| 0.129 | 0.099 | 0.129 | Thiol protease inhibitor | |||
| 0.117 | 0.087 | 0.146 | Glycogen synthase kinase-3 alpha inhibitor | 0.146 0.07 DBMET01575 | DBMET01575 | |
| 0.059 | 0.03 | 0.059 | Epithelial sodium channel blocker | 0.053 0.043 DBMET01575 | ||
| 0.056 | 0.027 | 0.056 | Phosphodiesterase 7A inhibitor | |||
| 0.06 | 0.032 | 0.065 | Pregnane X receptor antagonist | 0.065 0.021 DBMET01575 | DBMET01575 | |
| 0.053 | 0.025 | 0.068 | Dopamine beta hydroxylase inhibitor | 0.068 0.009 DBMET01575 | DBMET01575 | |
| 0.072 | 0.045 | 0.072 | Amidase inhibitor | |||
| 0.055 | 0.028 | 0.055 | Glycine transporter inhibitor | |||
| 0.093 | 0.066 | 0.097 | MAP kinase kinase 1 inhibitor | 0.097 0.061 DBMET01575 | DBMET01575 | |
| 0.059 | 0.032 | 0.059 | Nicotinic alpha7 receptor agonist | |||
| 0.096 | 0.069 | 0.096 | Glutamate (mGluR7) agonist | |||
| 0.053 | 0.028 | 0.053 | Glutamate (mGluR group I) agonist | |||
| 0.098 | 0.073 | 0.098 | Granulocyte macrophage colony stimulating factor antagonist | |||
| 0.06 | 0.036 | 0.072 | Beta 1 adrenoreceptor antagonist | 0.072 0.024 DBMET01575 | DBMET01575 | |
| 0.112 | 0.088 | 0.112 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.081 | 0.057 | 0.081 | Ca(v)3.1 blocker | |||
| 0.053 | 0.029 | 0.053 | Sodium/calcium exchanger inhibitor | |||
| 0.043 | 0.02 | 0.043 | Diamine oxidase inhibitor | |||
| 0.082 | 0.059 | 0.082 | Inducible nitric-oxide synthase inhibitor | |||
| 0.087 | 0.064 | 0.087 | Potassium channel activator | |||
| 0.04 | 0.017 | 0.04 | Ceramide glucosyltransferase inhibitor | 0.039 0.018 DBMET01575 | ||
| 0.06 | 0.038 | 0.06 | EphB4 antagonist | 0.06 0.038 DBMET01575 | ||
| 0.132 | 0.11 | 0.161 | Arachidonic acid antagonist | 0.161 0.076 DBMET01575 | DBMET01575 | |
| 0.038 | 0.016 | 0.038 | Acetylcholine M4 receptor agonist | |||
| 0.065 | 0.043 | 0.065 | Purinergic P2 antagonist | |||
| 0.049 | 0.027 | 0.049 | Adenylate cyclase 1 inhibitor | |||
| 0.114 | 0.092 | 0.114 | Sodium channel blocker | |||
| 0.035 | 0.015 | 0.035 | Cyclin E2 inhibitor | |||
| 0.036 | 0.016 | 0.036 | Vanilloid 4 antagonist | |||
| 0.06 | 0.04 | 0.06 | Phosphodiesterase 1A inhibitor | |||
| 0.032 | 0.011 | 0.032 | Myristoyl transferase inhibitor | |||
| 0.05 | 0.031 | 0.05 | AMPA receptor antagonist | |||
| 0.032 | 0.012 | 0.032 | Dopamine autoreceptor agonist | |||
| 0.109 | 0.09 | 0.109 | Cathepsin H inhibitor | |||
| 0.06 | 0.041 | 0.084 | Androgen agonist | 0.084 0.022 DBMET01575 | DBMET01575 | |
| 0.033 | 0.015 | 0.033 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | |||
| 0.064 | 0.045 | 0.066 | Beta 3 adrenoreceptor antagonist | 0.066 0.042 DBMET01575 | DBMET01575 | |
| 0.036 | 0.017 | 0.036 | Protein kinase (CK2) beta inhibitor | |||
| 0.056 | 0.038 | 0.056 | MAP kinase kinase 9 inhibitor | |||
| 0.03 | 0.013 | 0.033 | CC chemokine 1 receptor antagonist | 0.033 0.011 DBMET01575 | DBMET01575 | |
| 0.049 | 0.032 | 0.049 | Cholesterol esterase inhibitor | |||
| 0.03 | 0.013 | 0.03 | Calcium-sensing receptor agonist | |||
| 0.09 | 0.073 | 0.09 | Bile acid receptor antagonist | 0.089 0.077 DBMET01575 | ||
| 0.045 | 0.028 | 0.045 | Dihydrofolate reductase inhibitor | |||
| 0.029 | 0.013 | 0.029 | Thymidine phosphorylase inhibitor | |||
| 0.032 | 0.016 | 0.032 | CDK4/cyclin D3 inhibitor | 0.028 0.021 DBMET01575 | ||
| 0.029 | 0.013 | 0.029 | NMDA receptor glycine site antagonist | |||
| 0.02 | 0.004 | 0.02 | Cyclin D2 inhibitor | 0.015 0.006 DBMET01575 | ||
| 0.147 | 0.132 | 0.147 | Ca2+/calmodulin-dependent kinase II beta inhibitor | |||
| 0.101 | 0.086 | 0.116 | CDK3/cyclin E inhibitor | 0.116 0.061 DBMET01575 | DBMET01575 | |
| 0.089 | 0.074 | 0.089 | Sphingomyelinase inhibitor | |||
| 0.059 | 0.043 | 0.059 | CXC chemokine 4 receptor antagonist | |||
| 0.049 | 0.035 | 0.049 | Transforming growth factor beta 1 antagonist | |||
| 0.057 | 0.042 | 0.057 | Botulinum neurotoxin type A inhibitor | |||
| 0.054 | 0.04 | 0.054 | Immunoglobulin Fc receptor antagonist | |||
| 0.04 | 0.026 | 0.04 | AMPA 4 receptor antagonist | |||
| 0.117 | 0.103 | 0.133 | Cell wall synthesis inhibitor | 0.133 0.082 DBMET01575 | DBMET01575 | |
| 0.181 | 0.166 | 0.23 | Transcription factor STAT inhibitor | 0.23 0.102 DBMET01575 | DBMET01575 | |
| 0.039 | 0.025 | 0.039 | DNA gyrase subunit B inhibitor | |||
| 0.019 | 0.005 | 0.019 | Integrin beta2 antagonist | |||
| 0.077 | 0.063 | 0.077 | Neuropeptide Y antagonist | |||
| 0.026 | 0.012 | 0.026 | Urotensin II antagonist | 0.021 0.016 DBMET01575 | ||
| 0.03 | 0.017 | 0.03 | MAP3K8 inhibitor | |||
| 0.111 | 0.098 | 0.111 | Calcium channel blocker | |||
| 0.069 | 0.055 | 0.069 | Cathepsin G inhibitor | |||
| 0.077 | 0.064 | 0.082 | I kappa B kinase inhibitor | 0.082 0.058 DBMET01575 | DBMET01575 | |
| 0.037 | 0.024 | 0.037 | Purinergic P2X7 antagonist | |||
| 0.092 | 0.079 | 0.092 | Falcipain 3 inhibitor | |||
| 0.022 | 0.009 | 0.022 | Cyclin T1 inhibitor | |||
| 0.098 | 0.086 | 0.098 | Calcium channel (voltage-sensitive) blocker | |||
| 0.031 | 0.019 | 0.031 | AMPA 1 receptor antagonist | |||
| 0.027 | 0.015 | 0.027 | Complement factor 1r inhibitor | |||
| 0.059 | 0.048 | 0.059 | I kappa B kinase 2 inhibitor | 0.059 0.049 DBMET01575 | ||
| 0.04 | 0.028 | 0.04 | Nicotinic acid receptor 1 agonist | |||
| 0.059 | 0.048 | 0.059 | Cyclin A2 inhibitor | |||
| 0.065 | 0.054 | 0.065 | CDK1/cyclin B1 inhibitor | 0.061 0.059 DBMET01575 | ||
| 0.024 | 0.013 | 0.024 | Geranylgeranyltransferase inhibitor | |||
| 0.036 | 0.026 | 0.036 | Integrin alpha2 antagonist | |||
| 0.034 | 0.024 | 0.034 | Carnitine palmitoyltransferase 1 inhibitor | |||
| 0.059 | 0.05 | 0.059 | Phosphodiesterase 1C inhibitor | |||
| 0.02 | 0.01 | 0.02 | Alpha 2b adrenoreceptor agonist | |||
| 0.194 | 0.185 | 0.194 | Antithrombotic | |||
| 0.018 | 0.008 | 0.018 | CDK2/cyclin A3 inhibitor | |||
| 0.114 | 0.105 | 0.114 | Nav1.6 sodium channel blocker | |||
| 0.02 | 0.011 | 0.02 | Alpha 2c adrenoreceptor agonist | |||
| 0.05 | 0.042 | 0.05 | Dipeptidyl peptidase inhibitor | |||
| 0.03 | 0.022 | 0.031 | Lysophosphatidic acid 2 receptor antagonist | 0.031 0.02 DBMET01575 | DBMET01575 | |
| 0.019 | 0.011 | 0.019 | Complement factor D inhibitor | |||
| 0.018 | 0.01 | 0.018 | CC chemokine 9 receptor antagonist | |||
| 0.022 | 0.014 | 0.022 | Kainate receptor 1 antagonist | |||
| 0.014 | 0.006 | 0.014 | Melatonin 5 antagonist | |||
| 0.051 | 0.043 | 0.051 | Myc inhibitor | |||
| 0.082 | 0.074 | 0.088 | ATPase (Vacuolar H+) inhibitor | 0.088 0.059 DBMET01575 | DBMET01575 | |
| 0.03 | 0.023 | 0.03 | Epoxide hydrolase 1 inhibitor | |||
| 0.036 | 0.029 | 0.036 | Melanocortin 1 antagonist | |||
| 0.033 | 0.026 | 0.033 | Carnitine palmitoyltransferase inhibitor | |||
| 0.042 | 0.035 | 0.042 | Dipeptidyl peptidase IV inhibitor | |||
| 0.046 | 0.04 | 0.046 | Bombesin 2 receptor antagonist | |||
| 0.055 | 0.048 | 0.055 | Cyclin A inhibitor | |||
| 0.076 | 0.07 | 0.076 | GABA A receptor agonist | |||
| 0.18 | 0.174 | 0.18 | Thyroid hormone beta antagonist | |||
| 0.031 | 0.025 | 0.031 | Protein kinase C beta II inhibitor | |||
| 0.042 | 0.036 | 0.042 | Poly(ADP-ribose) polymerase inhibitor | |||
| 0.059 | 0.054 | 0.059 | Histone deacetylase SIRT3 inhibitor | |||
| 0.069 | 0.064 | 0.069 | CC chemokine receptor antagonist | |||
| 0.034 | 0.03 | 0.034 | Glutamate (mGluR3) antagonist | |||
| 0.087 | 0.083 | 0.087 | Nitric-oxide synthase inhibitor | |||
| 0.032 | 0.028 | 0.033 | CDK6/cyclin D3 inhibitor | 0.033 0.024 DBMET01575 | DBMET01575 | |
| 0.072 | 0.069 | 0.072 | Viral attachment inhibitor | |||
| 0.011 | 0.008 | 0.011 | Imidazoline I2 receptor antagonist | |||
| 0.02 | 0.017 | 0.02 | Factor XIII inhibitor | |||
| 0.09 | 0.087 | 0.09 | EphA2 antagonist | |||
| 0.02 | 0.018 | 0.02 | Alpha 1a adrenoreceptor agonist | |||
| 0.023 | 0.021 | 0.023 | 5 Hydroxytryptamine 4 agonist | |||
| 0.025 | 0.023 | 0.025 | 5 Hydroxytryptamine 1D agonist | |||
| 0.083 | 0.082 | 0.083 | Potassium channel (Voltage-sensitive) activator | |||
| 0.052 | 0.053 | 0.055 | Carbamoyl phosphate synthetase inhibitor | 0.055 0.049 DBMET01575 | DBMET01575 | |
| 0.058 | 0.061 | 0.077 | Phenylalanine 4-hydroxylase inhibitor | 0.077 0.04 DBMET01575 | DBMET01575 | |
| 0.068 | 0.072 | 0.125 | Estrogen receptor alpha antagonist | 0.125 0.017 DBMET01575 | DBMET01575 | |
| 0.057 | 0.061 | 0.075 | Beta adrenoreceptor antagonist | 0.075 0.031 DBMET01575 | DBMET01575 | |
| 0.029 | 0.034 | 0.046 | Phosphoglycerate kinase inhibitor | 0.046 0.015 DBMET01575 | DBMET01575 | |
| 0.015 | 0.023 | 0.021 | Estrogen-related receptor gamma agonist | 0.021 0.009 DBMET01575 | DBMET01575 | |
| 0.036 | 0.045 | 0.052 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.052 0.013 DBMET01575 | DBMET01575 | |
| 0.068 | 0.081 | 0.106 | Androgen antagonist | 0.106 0.043 DBMET01575 | DBMET01575 | |
| 0.02 | 0.033 | 0.027 | Liver X receptor beta antagonist | 0.027 0.022 DBMET01575 | DBMET01575 | |
| 0.08 | 0.093 | 0.086 | Carbonic anhydrase III inhibitor | 0.086 0.081 DBMET01575 | DBMET01575 | |
| 0.075 | 0.089 | 0.089 | Prolactin inhibitor | 0.089 0.068 DBMET01575 | DBMET01575 | |
| 0.064 | 0.079 | 0.129 | Macrophage migration inhibitory factor inhibitor | 0.129 0.022 DBMET01575 | DBMET01575 | |
| 0.039 | 0.054 | 0.053 | Beta 2 adrenoreceptor antagonist | 0.053 0.032 DBMET01575 | DBMET01575 | |
| 0.088 | 0.104 | 0.109 | DOPA decarboxylase inhibitor | 0.109 0.06 DBMET01575 | DBMET01575 | |
| 0.023 | 0.041 | 0.043 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.043 0.014 DBMET01575 | DBMET01575 | |
| 0.059 | 0.076 | 0.081 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.081 0.05 DBMET01575 | DBMET01575 | |
| 0.023 | 0.045 | 0.032 | ATP citrate lysase inhibitor | 0.032 0.021 DBMET01575 | DBMET01575 | |
| 0.041 | 0.071 | 0.061 | Acetylcholine M3 receptor antagonist | 0.061 0.04 DBMET01575 | DBMET01575 | |
| 0.048 | 0.085 | 0.088 | Histidine decarboxylase inhibitor | 0.088 0.038 DBMET01575 | DBMET01575 | |
| 0.074 | 0.118 | 0.133 | Adenylate cyclase inhibitor | 0.133 0.058 DBMET01575 | DBMET01575 | |
| 0.138 | 0.183 | 0.166 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.166 0.114 DBMET01575 | DBMET01575 | |
| 0.112 | 0.159 | 0.138 | Pyruvate kinase inhibitor | 0.138 0.127 DBMET01575 | DBMET01575 | |
| 0.017 | 0.068 | 0.032 | Nicotinic acid receptor agonist | 0.032 0.031 DBMET01575 | DBMET01575 | |
| 0.045 | 0.097 | 0.073 | Porphobilinogen synthase inhibitor | 0.073 0.053 DBMET01575 | DBMET01575 | |
| 0.015 | 0.073 | 0.027 | Thyroid hormone agonist | 0.027 0.017 DBMET01575 | DBMET01575 | |
| 0.05 | 0.111 | 0.064 | Beta 2 adrenoreceptor agonist | 0.064 0.034 DBMET01575 | DBMET01575 | |
| 0.066 | 0.133 | 0.081 | Estrogen-related receptor beta agonist | 0.081 0.064 DBMET01575 | DBMET01575 | |
| 0.17 | 0.248 | 0.199 | Interleukin 2 agonist | 0.199 0.192 DBMET01575 | DBMET01575 | |
| 0.135 | 0.216 | 0.21 | Prostaglandin dehydrogenase inhibitor | 0.21 0.15 DBMET01575 | DBMET01575 | |
| 0.08 | 0.164 | 0.119 | Src kinase inhibitor | 0.119 0.109 DBMET01575 | DBMET01575 | |
| 0.104 | 0.195 | 0.15 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.15 0.073 DBMET01575 | DBMET01575 | |
| 0.09 | 0.19 | 0.119 | Vanilloid 1 agonist | 0.119 0.09 DBMET01575 | DBMET01575 | |
| 0.056 | 0.157 | 0.124 | c-Src kinase inhibitor | 0.124 0.072 DBMET01575 | DBMET01575 | |
| 0.027 | 0.138 | 0.058 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.058 0.032 DBMET01575 | DBMET01575 | |
| 0.125 | 0.259 | 0.2 | Transcription factor NF kappa B inhibitor | 0.2 0.169 DBMET01575 | DBMET01575 | |
| 0.006 | 0.148 | 0.015 | Thyroid hormone alpha agonist | 0.015 0.014 DBMET01575 | DBMET01575 | |
| 0.027 | 0.192 | 0.075 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.075 0.06 DBMET01575 | DBMET01575 | |
| 0.042 | 0.255 | 0.159 | Estrogen receptor beta antagonist | 0.159 0.014 DBMET01575 | DBMET01575 | |
| 0.15 | 0.392 | 0.244 | Calcium channel L-type activator | 0.244 0.212 DBMET01575 | DBMET01575 | |
| 0.052 | 0.308 | 0.133 | Interleukin 4 antagonist | 0.133 0.068 DBMET01575 | DBMET01575 | |
| 0.046 | 0.312 | 0.161 | Estrogen antagonist | 0.161 0.02 DBMET01575 | DBMET01575 | |
| 0.003 | 0.644 | 0.035 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.035 0.024 DBMET01575 | DBMET01575 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |